HSPA1A and amyotrophic lateral sclerosis: Arimoclomol, a compound that increases Hsp70 proteins as well as other Hsp chaperones52, recently failed phase II/III clinical trials for the treatment of ALS (Clinicaltrials.gov identifier NCT03491462).